| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Adage Capital Management, L.P. | 5.2% | $24,500,946 | 6,551,055 | Adage Capital Management, L.P. | 31 Dec 2024 |
As of 30 Sep 2025, 1 institutional investors reported holding 27,985 shares of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI). This represents 0.02% of the company’s total 126,468,243 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 27,985 | $183,022 | $6.54 | 1 | |
| 2025 Q2 | 27,985 | $120,615 | -$1,211,880 | $4.31 | 1 |
| 2025 Q1 | 352,017 | $1,316,544 | -$55,318,808 | $3.74 | 2 |
| 2024 Q4 | 60,912,948 | $41,204,113 | -$289,373 | $0.68 | 87 |
| 2024 Q3 | 59,278,240 | $49,194,051 | -$6,331,563 | $0.83 | 90 |
| 2024 Q2 | 67,556,361 | $58,626,062 | -$7,639,125 | $0.87 | 114 |
| 2024 Q1 | 74,702,822 | $112,801,347 | +$3,989,777 | $1.51 | 111 |
| 2023 Q4 | 73,344,053 | $63,441,322 | -$4,574,345 | $0.86 | 118 |
| 2023 Q3 | 76,219,647 | $102,134,785 | -$10,719,386 | $1.34 | 117 |
| 2023 Q2 | 80,450,419 | $144,011,333 | -$18,617,679 | $1.79 | 133 |
| 2023 Q1 | 87,557,859 | $340,123,767 | -$32,799,976 | $3.89 | 128 |
| 2022 Q4 | 98,414,676 | $334,456,268 | +$99,576,581 | $3.40 | 152 |
| 2022 Q3 | 66,862,684 | $365,052,989 | -$620,374 | $5.46 | 142 |
| 2022 Q2 | 67,139,765 | $302,788,902 | -$7,006,335 | $4.51 | 144 |
| 2022 Q1 | 68,286,528 | $501,776,522 | +$108,241,216 | $7.37 | 134 |
| 2021 Q4 | 54,170,305 | $347,414,468 | -$3,383,122 | $6.43 | 138 |
| 2021 Q3 | 57,408,855 | $334,396,841 | -$25,823,482 | $5.82 | 130 |
| 2021 Q2 | 58,982,285 | $608,669,781 | -$13,934,484 | $10.32 | 147 |
| 2021 Q1 | 59,160,795 | $622,242,344 | -$49,072,460 | $10.52 | 163 |
| 2020 Q4 | 63,829,194 | $988,058,899 | -$54,468,075 | $15.48 | 165 |
| 2020 Q3 | 65,150,667 | $951,174,601 | -$110,130,293 | $14.60 | 155 |
| 2020 Q2 | 69,738,739 | $1,320,807,090 | +$45,201,421 | $18.94 | 155 |
| 2020 Q1 | 67,992,711 | $1,305,743,291 | +$217,084,502 | $19.21 | 135 |
| 2019 Q4 | 58,955,103 | $1,130,098,649 | -$54,693,103 | $19.17 | 146 |
| 2019 Q3 | 58,481,490 | $562,607,545 | +$83,519,427 | $9.62 | 105 |
| 2019 Q2 | 51,164,991 | $306,457,439 | +$3,407,218 | $5.99 | 102 |
| 2019 Q1 | 51,219,533 | $299,625,643 | -$24,705,356 | $5.84 | 101 |
| 2018 Q4 | 51,412,770 | $481,695,108 | +$75,184,187 | $9.37 | 116 |
| 2018 Q3 | 43,286,107 | $737,162,850 | -$818,029 | $17.03 | 117 |
| 2018 Q2 | 43,354,403 | $736,589,579 | +$217,013,290 | $16.99 | 108 |
| 2018 Q1 | 30,891,981 | $414,567,351 | +$174,090 | $13.42 | 87 |
| 2017 Q4 | 31,007,107 | $297,662,901 | +$20,343,235 | $9.60 | 88 |
| 2017 Q3 | 28,741,389 | $315,542,785 | +$10,686,137 | $10.98 | 74 |
| 2017 Q2 | 27,780,067 | $251,407,245 | +$6,202,394 | $9.05 | 71 |
| 2017 Q1 | 26,846,913 | $344,713,183 | +$45,322,035 | $12.84 | 79 |
| 2016 Q4 | 25,467,293 | $239,390,343 | +$21,237,489 | $9.40 | 85 |
| 2016 Q3 | 23,180,959 | $225,551,522 | +$31,499,955 | $9.73 | 77 |
| 2016 Q2 | 20,044,622 | $134,499,864 | -$8,387,552 | $6.71 | 73 |
| 2016 Q1 | 21,165,907 | $188,770,460 | -$5,334,988 | $8.92 | 76 |
| 2015 Q4 | 21,560,134 | $285,674,019 | -$24,016,754 | $13.25 | 86 |
| 2015 Q3 | 23,545,780 | $247,934,145 | -$6,616,775 | $10.53 | 87 |
| 2015 Q2 | 22,391,611 | $609,266,884 | +$40,371,623 | $27.21 | 88 |
| 2015 Q1 | 20,794,207 | $636,290,225 | +$53,545,677 | $30.61 | 85 |
| 2014 Q4 | 18,742,387 | $701,526,058 | +$50,285,065 | $37.43 | 81 |
| 2014 Q3 | 16,817,880 | $587,612,971 | +$52,881,540 | $34.94 | 70 |
| 2014 Q2 | 15,117,534 | $703,718,591 | +$235,116,570 | $46.55 | 78 |
| 2014 Q1 | 10,072,951 | $310,923,978 | +$33,552,565 | $30.89 | 59 |